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Background: Advanced pancreatic cancer (APC), beside its high mortality, causes the highest rates of venous
thromboembolic events (VTE). Enoxaparin, a low molecular weight heparin (LMWH), is effective in prevention and
treatment of VTE. Some small studies indicated that this benefit might extend to patients with cancer and probably
prolong survival due to independent mechanisms. We initiated this safety investigation to get feasibility information
on intensified chemotherapy combined with LMWH in outpatients with APC treated in 1st line.
Methods: The trial was a prospective, open-label, single center investigation in outpatients with inoperable pancreatic
cancer who were treated with intensified first-line chemotherapy along with concomitant application of subcutaneous
LMWH. The combined chemotherapy consisted of gemcitabine 1 g/m2 (30 min), 5-FU 750 mg/m2 (24 h), folinic acid
200 mg/m2 (30 min), and Cisplatin 30 mg/m2 (90 min) on day 1 and 8; q3w for the first 12 weeks (GFFC) followed by
gemcitabine alone in patients without cancer progression. The simultaneous application of prophylactic enoxaparin
started on day 1 of chemotherapy with a fixed dose of 40 mg daily. Statistical analyses were performed using R 3.01
with software package CMPRSK and SPSS software v19.0.
Results: The investigation was stopped after recruitment of 19 patients. At this time 15 patients had completed the
required 12 weeks of treatment. Based on 71 cycles of GFFC + enoxaparin (median 4/pt [range: 2–4]) and 108 cycles of
single-agent gemcitabine + enoxaparin (median 4/pt [range: 0–18]) the cumulative frequency of NCI-CTC toxicities
grade 3/4 was below 10%. One case (5%) of a symptomatic non-lethal thromboembolic event was observed while
receiving LMWH treatment. No severe bleeding event as defined in the protocol has been observed. The median
overall survival was 10.05 [95% CI: 8.67-18.14] months.
Conclusions: The addition of enoxaparin to GFFC chemotherapy is feasible, safe and does not appear to affect the
efficacy or the toxicity profile of the chemotherapy regimen in patients with advanced pancreatic adenocarcinoma.
Based on these findings we have initiated the randomized CONKO-004 trial to examine whether enoxaparin reduces
the incidence of thromboembolic events or increases overall outcome.
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Pancreatic adenocarcinoma is an aggressive cancer type
with early extensive local invasion, rapid systemic spread
combined with a high resistance to chemotherapy. This
is accompanied by a case fatality rate of 90% and thus
constitutes the fourth most-frequent cause of death from
solid cancer in the western world [1]. In patients with
non-resectable advanced pancreatic cancer (APC) me-
dian overall survival without effective systemic antican-
cer treatment is not higher than 4 months [2-4]. Despite
intensive anticancer research in the last decade, five year
overall survival in patients with APC is still less than 5%
[5]. Single agent gemcitabine (GEM) has become the
standard first-line chemotherapy for pancreatic cancer
15 years ago [2]. More recent trials using combination
regimens with or without gemcitabine showed improve-
ments in cancer control-rate and even survival advantages,
most pronounced for patients with better performance
status [6-9]. Thus, patients with good performance status
are indicated for intensified treatment with combined
chemotherapy regimens [9,10].
Venous thromboembolic events (VTE) are considered
to be a commonly accurring major lethal complication
in cancer patients. Population based case–control trials
display a cumulative incidence of VTE of up to six-fold
in cancer patients [11]. Cancer types with highest inci-
dence rates are advanced malignancies of the brain, pan-
creas, lung, and stomach [12-14]. As compared to more
limited stages metastatic disease results in a 4 to 13-fold
elevated VTE risk, which is further increased by systemic
anticancer therapy [14]. The bidirectional interaction be-
tween cancer and hemostasis not only leads to activation
of blood cells and the coagulation system resulting in
clinically relevant thromboembolism but these pro-
cesses are also under suspicion to enhance cancer growth
and metastatic spread [15]. VTE are considered to be a
prognostic-negative factor [11,12] and small studies showed
astonishing survival advantages using heparin as prophy-
lactic treatment to prevent VTE [16]. Based on these as-
sumptions our CONKO study group planned to conduct
a randomized trial to investigate the impact of low
molecular weight heparin (LMWH) in a prospective set-
ting in patients with advanced pancreatic cancer
undergoing first line therapy, the CONKO-004 trial [17].
During the preliminary stages we had to undertake a
pilot trial to get information on safety and feasibility
of combined chemotherapy with simultaneous treat-
ment of the LMWH enoxaparin in patients with ad-
vanced pancreatic cancer who are at high risk of
gastrointestinal bleeding due to local cancer spread. The
toxicity profile, feasibility, and maximum tolerable dosage
of the combination of gemcitabine/5-FU/Folinic Acid/Cis-
platin was investigated in a past phase-I trial of our
study group [18].Methods
Design and treatment
The trial was a prospective, open-label, single center in-
vestigation in patients with advanced pancreatic cancer
who were treated with first-line chemotherapy in an out-
patient setting. The intensified treatment consisted of
gemcitabine 1 g/m2 (30 min), 5-FU 750 mg/m2 (24 h),
folinic acid 200 mg/m2 (30 min), and cisplatin 30 mg/m2
(90 min) on day 1 and 8; q3w. The concomitant applica-
tion of enoxaparin started on day 1 of chemotherapy with
a fixed dose of 40 mg daily until cancer progression. Be-
yond the initial 3 months of intensified 1st-line chemo-
therapy all patients without cancer progression received
further treatment with single agent gemcitabine and enox-
aparin to prevent patients from cumulative toxicities. Dose
adjustment for enoxaparin was recommended in patients
with impaired kidney function or thrombocytopenia within
the study according to NCI-CTC (National Cancer Insti-
tute Common Toxicity Criteria) guidelines to minimize
bleeding risk. Dose adjustment for chemotherapy dosage
was realised by protocol-defined regulations [18]. Prophy-
lactic antiemetic therapy and supportive care were pro-
vided according to individual symptoms and demand.
The study used a sequential design to be able to stop
the feasibility investigation in case of severe side effects.
After inclusion of three consecutive patients a hold of
recruitment was arranged until all three patients received
at least 4 weeks of concomitant enoxaparin treatment. In
absence of inacceptable toxicity by confirmation of the
protocol committee the recruitment was continued until a
minimum of 15 patients received at least 12 weeks con-
comitant enoxaparin treatment. Patients were followed up
until death of any reason or lost to follow-up.
The trial was approved by the scientific and research
ethics committee of our institution (Ethikkommission der
Charité - Universitaetsmedizin Berlin). The investigation
was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines and within
the CONSORT guidelines. Furthermore, the national
principles for the proper execution of the clinical examin-
ation of drugs (Bundesanzeiger No. 243 of 30.12.1987),
the national regulations of the German drug law, and the
German drug test guidelines were adhered. Trial registra-
tion: Clinical Trials NCT01945879.
Eligibility criteria
Main inclusion criteria were: ambulatory patients with histo-
logically confirmed APC, no previous radio- or chemother-
apy, Karnofsky Performance Status (KPS) ≥ 60%; measurable
tumour lesion confirmed by computed tomography (CT)
or magnetic resonance imaging (MRI) within the last
14 days, no VTE within the last 2 years, adequate compli-
ance and home residence within geographical proximity
to our department (allowing an adequate follow-up),
Table 1 Demographic and baseline characteristics
Characteristic: N = 19 (100%) Chemotherapy + Enoxaparin
Age – Years
Median [range] 59 [46 – 74]
Sex – no. (%)
Female 6 (32)
Male 13 (68)
KPS – no. (%)
60% - 70% 2 (11)
80% - 100% 17 (89)
Stage – no. (%)
M0 6 (32)
M1 13 (68)




Primary cancer – no. (%) 12 (63)
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thrombocytes 100 × 109/l), age ≥ 18 years.
Patients were excluded in case of pre-existing indica-
tion for anticoagulation, major bleeding events within
the last 2 weeks or severe impairment of coagulation, ac-
tive gastrointestinal ulcers or major surgery within the last
2 weeks, body weight < 45 kg or > 100 kg, pregnancy/lacta-
tion or insufficient contraception during study or severely
impaired renal function (creatinine clearance < 30 ml/min).
All patients had to provide written informed consent.
Outcome measures
Primary investigation included the feasibility, the toxicity
profile, and probable drug interactions. The first step
was the analysis of safety data of the initial three patients
after completing their first 4 weeks of combined treat-
ment. On condition that there is no more than one pa-
tient with a toxicity of NCI-CTC grade 3/4 and no event
of severe bleeding, the recruitment would be continued
(protocol committee consensus). The final treatment
feasibility and safety would be approved if the incidence
of predefined severe grade 3/4 toxicities (NCI-CTC)
would be no higher than 20% as well as the incidence of
predefined severe, life threatening bleeding events would
be no higher than 20% in a minimum of 15 patients
under treatment duration of at least 12 weeks.
Secondary aims were overall survival (OS), influence of
prognostic factors and the rate of symptomatic venous
thromboembolic events and severe bleedings. Staging CT
or MRI was performed at least every 12 weeks (earlier in
case of suspected progression). According to safety aspects
we documented severe bleedings in the event of short
term decline of hemoglobin level (≥ 2 g/dl/48 h) in ab-
sence of other evidence (e.g. hemolysis) and/or the
need for at least two red blood cell concentrates in case
of confirmed blood loss and/or the clinical occurrence of
serious apparent bleeding in parenchyma, muscle or cere-
brum. The highest grade of a hematologically or non-
hematologically toxicity during a cycle was recorded for
the analysis.
Statistical methods
Statistical analyses were performed using R 3.01 with
software package CMPRSK and SPSS software 19.0.
Results
For the first three patients no intense toxicity, particu-
larly no severe bleeding event, was observed within the
required 4 weeks of treatment. Hence the recruitment
was continued to get a minimum of 15 patients receiving
combined chemotherapy and concomitant enoxaparin
over a duration of at least 12 weeks.
As 15 patients completed the 12 weeks of treatment a
total number of 19 patients were recruited (Table 1). 2patients had progressive disease within the 12 weeks and
decreased rapidly in performance status without qualify-
ing for second line treatment. The remaining 17 patients
were staged at 12 weeks, of which 15 patients had a
stable disease and were getting further treatment with
gemcitabine alone simultaneous with enoxaparin, whereas
2 patients had documented progressive disease and were
switched to paclitaxel second-line regimen without enoxa-
parin treatment.
The analysis of cumulative toxicities was based on 71
(median 4/pt [range:2–4]) cycles of GFFC with enoxaparin
and 108 (median 4/pt [range:0–18]) cycles of single-agent
gemcitabine with enoxaparin (Figure 1). The incidence of
NCI-CTC grade 3/4 toxicities was below 10%, most fre-
quent side effect was neutropenia (grade 3: 12 cycles,
grade 4: 2 cycles) and thrombocytopenia (grade 3: 1 cycle).
During the course of GFFC the dose of cisplatin was re-
duced by 50% in 3 patients due to elevated serum creatin-
ine levels, up to grade 2 in one patient. No grade 3/4
nausea or vomiting occurred. One case of symptomatic
deep venous thrombosis with consecutive non-lethal pul-
monary embolism was observed while receiving prophy-
lactic LMWH treatment (5%). No patient stopped the
subcutaneous heparin injections due to occurrence of
local side irritations or generally inconvenience. No severe
bleeding events as defined in the protocol were observed
Figure 1 Hematological and non-hematological toxicities
(no. out of 179 cycles). Numbers represent the count of
treatment cycles with corresponding toxicity.
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sponding follow-up of 30 days.
The median overall survival was 10.05 [95% CI: 8.67-
18.14] months (see Figure 2). Two out of 19 patients
were lost to follow-up and were censored at the time of
last documented visit. The multivariate analysis of over-
all survival showed no significant effect on survival by a
single characteristic (Figure 3). Best trend was observedFigure 2 Kaplan-Meier plot for overall survival.for patients with previous curatively intended cancer re-
section followed by cancer recurrence versus patients
with primary inoperable pancreatic adenocarcinoma.
Discussion
This investigation was conducted to assess the use of
intensified chemotherapy together with simultaneous
application of heparin. The application of medical antic-
oagulation for cancer patients was still discussed over
the last decade, even for inpatients or patients with
confirmed thrombosis. The assumed higher incidence
of severe bleeding events due to medical anticoagula-
tion, especially in patients with advanced gastrointes-
tinal malignancies, reduced the number of sufficient
treated patients in the past and thus may lead to im-
paired overall survival [12,19].
This open label phase II feasibility investigation used
intensified chemotherapy and simultaneous enoxaparin
treatment in patients with first line chemotherapy. The
dosage of enoxaparin to be used in our trial has been in-
tensively discussed in terms of pre-existing prevention
studies in other indications. Results from the PRINCE
[20] and MEDENOX [21,22] studies demonstrated ef-
fective and well-tolerated VTE prevention in patients with
severe cardiopulmonary disease using the LMWH enoxa-
parin. The given dosages in the MEDENOX trial were set
at a high prophylactic level of 40 mg daily versus placebo
and also in the PRINCE trial with 40 mg daily versus
5000 IU unfractioned heparin 3× daily. Thus 40 mg enox-
aparin once a day was considered to be the minimal dose
for primary symptomatic VTE prevention.
We used a safety step design to prevent patients from
harmful increased toxicities due to the combination. The
observed side effects were consistent with respect to the
applied chemotherapy and were similar to those in our
phase I trial [18]. We therefore continued the investiga-
tion without need of modification of the regimen. Even
the addition of heparin does not lead to increased toxic-
ities. We suspected a raise in the local bleeding rate in
our advanced pancreatic cancer patients by potential
cancer infiltration of the stomach or duodenum. Major
bleeding rates for patients with solid cancer using warfarin
were 42% and 14% for controls in 431 patients [23], in our
safety trial we therefore decided to accept no higher rate
than 20% using prophylactic anticoagulation with enoxa-
parin. Fortunately we did not observe any patient with se-
vere bleeding under concomitant application of 40 mg
enoxaparin daily. Only one patient had a thromboembolic
event while getting enoxaparin (5%), whereas the sup-
posed rate of thromboembolic events without heparin use
would be 15-20% [11].
We further observed a slightly increased overall survival
compared to gemcitabine monotherapy [2,9,24]. This find-
ing and the open discussion about an independent effect
Figure 3 Forest plot of prognostic factors.
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has to be investigated by a randomized trial in a larger set-
ting [17]. On the other hand this observed effect is com-
monly seen in phase II studies with the potential bias of
unconscious patient selection and the addition of placebo
effects [7,10]. But besides these considerations we can at
least assume that the efficacy of the treatment is not nega-
tively affected.
The finding of this investigation regarding feasibility
and safety gives us confidence for using the researched
combination in a larger trial to investigate the effect of
heparin in a randomized setting.
Conclusions
In summary, the addition of enoxaparin to GFFC is feas-
ible, safe and does not appear to affect the activity or the
toxicity profile of the chemotherapy regimen in patients
with advanced pancreatic adenocarcinoma. To examine
whether enoxaparin reduces the incidence of thrombo-
embolic events and increases survival, we have initiated a
randomized investigation study of GFFC (or single-agent
gemcitabine for patients with impaired performance sta-
tus) with or without enoxaparin (CONKO-004) [17].Competing interests
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